Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study

Abstract

Our study found that linezolid was as effective as vancomycin in suppressing colony counts in MRSA- or MRSE-infected vascular Dacron grafts in rats.

Incidence and Susceptibility Pattern of Methicillin Resistant Coagulase-negative Staphylococci Isolated From a Tertiary Care Hospital of Pakistan

“…None of the organisms were found to be resistant against linezolid. This is in accordance to a study by Sacar et al showing that the antibiotic was highly effective in reducing the colony counts in MRSE-infected vascular Dacron grafts in rats which was comparable to the efficacy of vancomycin in the same study ( 10 ). Chlorampheniacol was moderately effective with 21.9% resistance ( Figure 2 ).…”

Mesenchymal stem cells have significant anti-infective effect on methicillin-resistant Staphylococcus epidermidis vascular graft infections

“…The development of resistance and reduction of susceptibility [35] to methicillin at the beginning and vancomycin later by the staphylococci gave rise to investigations for alternative treatment options for vascular graft infections. [10] Tigecycline, the first generation of glycycline antibiotics, is one of the choices of treatment in infections caused by methicillin-resistant Staphylococcus aureus (MRSA), MRSE, and vancomycin-resistant enterococcus infections. [36,37] Thus, it is one of the alternative antimicrobial treatments for vascular graft infections resistant to methicillin or vancomycin.…”

“…[4] Against alternative treatment approaches as in situ graft replacement [7] and graft retention with thorough debridement, [8] removal of the graft followed by extraanatomic bypass revascularization is the traditional treatment method for vascular graft infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) is the common cause of these infections, [9,10] which usually does not respond to antibiotherapy, requiring graft excision. [11] Mesenchymal stem cells (MSCs) have immunomodulatory and anti-inflammatory effect achieved by change in T helper subtypes, regulation of the activity of macrophages and changing proliferation, differentiation and immunsecretion characteristics of B cells.…”

Local Vancomycin Effectively Reduces Surgical Site Infection at Implant Site in Rodents

“…In previous rat studies with subcutaneous Dacron implants and S. aureus infection, the systemic vancomycin dose to reduce SSI by at least 3 log units after 1 week was in the range of 7 to 10 mg/kg. [21][22][23] However, these Dacron implants were more porous, and so the optimal systemic vancomycin dose for the metal discs may be higher. There have also been studies in rats on using vancomycin powder on infected orthopedic implants, 24,25 but that milieu is so different from the stimulator implant sites that the therapeutic doses cannot be compared.…”